Can you take Atoncy with Galantamine?

Galantamine has a major potential interaction with Arrhythmia.

Due to their pharmacological action, cholinesterase inhibitors can have a vagotonic effect on the sinoatrial and atrioventricular nodes producing bradycardia or heart block. Therapy with cholinesterase inhibitors should be administered cautiously in patients with preexisting bradycardia or underlying cardiac conduction abnormalities. Syncopal episodes have been reported. Atropine may be used to reverse bradycardia produced by cholinesterase inhibitors.

Galantamine has a major potential interaction with Asthma.

Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm. Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma, or obstructive pulmonary disease. Respiratory function should be closely monitored for the occurrence of respiratory adverse reactions. Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.

The atomoxetine in Atoncy has a major potential interaction with Bipolar Disorder.

Atomoxetine increased the risk of suicidal ideation in pediatric patients with ADHD, and patients should be monitored closely for suicidal thoughts and behavior, clinical worsening, or unusual behavioral changes, especially during initial therapy or dosage changes. Before initiating atomoxetine, patients should be screened for bipolar disorder risk factors, and discontinuation should be considered if treatment-emergent psychotic or manic symptoms occur.

The atomoxetine in Atoncy has a moderate potential interaction with Cardiovascular Conditions and Disorders.

Atomoxetine should be used with caution both in patients with conditions that may predispose them to hypotension or abrupt changes in heart rate or blood pressure, and in patients with underlying medical conditions that could be worsened by increases in blood pressure or heart rate, such as hypertension, tachycardia, cardiovascular disease, or cerebrovascular disease. Heart rate and blood pressure should be measured at baseline, following atomoxetine dosage increases, and periodically during therapy to detect clinically important increases.

The atomoxetine in Atoncy has a moderate potential interaction with Cerebral Vascular Disorder.

Atomoxetine should be used with caution both in patients with conditions that may predispose them to hypotension or abrupt changes in heart rate or blood pressure, and in patients with underlying medical conditions that could be worsened by increases in blood pressure or heart rate, such as hypertension, tachycardia, cardiovascular disease, or cerebrovascular disease. Heart rate and blood pressure should be measured at baseline, following atomoxetine dosage increases, and periodically during therapy to detect clinically important increases.

Galantamine has a major potential interaction with COPD.

Cholinesterase inhibitors inhibit the hydrolysis of acetylcholine. The enhanced effect of acetylcholine produces constriction of the bronchi, increased bronchial secretions, and bronchospasm. Therapy with cholinesterase inhibitors should be administered cautiously in patients with respiratory dysfunction, history of asthma, or obstructive pulmonary disease. Respiratory function should be closely monitored for the occurrence of respiratory adverse reactions. Use of atropine along with discontinuation of the cholinesterase inhibitor may be required for serious respiratory distress.

The atomoxetine in Atoncy has a major potential interaction with Depression.

Atomoxetine increased the risk of suicidal ideation in pediatric patients with ADHD, and patients should be monitored closely for suicidal thoughts and behavior, clinical worsening, or unusual behavioral changes, especially during initial therapy or dosage changes. Before initiating atomoxetine, patients should be screened for bipolar disorder risk factors, and discontinuation should be considered if treatment-emergent psychotic or manic symptoms occur.

The atomoxetine in Atoncy has a major potential interaction with Glaucoma, Narrow Angle.

The use of atomoxetine is contraindicated in patients with narrow angle glaucoma. In clinical trials, atomoxetine use was associated with an increased risk of mydriasis.

The atomoxetine in Atoncy has a major potential interaction with Heart Disease.

Atomoxetine is contraindicated in patients with severe cardiac or vascular disorders whose condition would be expected to deteriorate if they had clinically important increase in blood pressure (e.g., 15 to 20 mmHg) or heart rate (e.g., 20 beats per minute). Atomoxetine generally should not be used in pediatric patients with known serious structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, or other serious cardiac problems, and clinicians should consider not treating adults with clinically significant cardiac abnormalities, due to the risk of sudden death. Carefully assess cardiovascular history and perform physical exam before treatment, conduct further cardiac evaluation when indicated, and stop atomoxetine pending prompt cardiac evaluation if exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease occur.

The atomoxetine in Atoncy has a major potential interaction with High Blood Pressure.

CNS stimulants increase blood pressure and heart rate; the use of some agents may be contraindicated in patients with severe/uncontrolled hypertension. Caution should be used when administering to patients with preexisting high blood pressure (even mild hypertension) and other cardiovascular conditions. All patients under treatment should be regularly monitored for potential tachycardia and hypertension.

The atomoxetine in Atoncy has a moderate potential interaction with Hypotension.

Atomoxetine should be used with caution both in patients with conditions that may predispose them to hypotension or abrupt changes in heart rate or blood pressure, and in patients with underlying medical conditions that could be worsened by increases in blood pressure or heart rate, such as hypertension, tachycardia, cardiovascular disease, or cerebrovascular disease. Heart rate and blood pressure should be measured at baseline, following atomoxetine dosage increases, and periodically during therapy to detect clinically important increases.

The atomoxetine in Atoncy has a moderate potential interaction with Liver Disease.

Atomoxetine can cause severe liver injury. Atomoxetine exposure is increased in patients with moderate or severe hepatic impairment, and a lower dosage is recommended in these patients. Atomoxetine should be permanently discontinued in patients with jaundice or laboratory evidence of liver injury. Liver enzyme and function tests should be obtained at the first symptom or sign of liver dysfunction.

Galantamine has a moderate potential interaction with Liver Disease.

In patients with moderate hepatic impairment (Child-Pugh score of 7 to 9), the dosage of galantamine or benzgalantamine should generally not exceed 16 mg/day or 20 mg/day, respectively. The use of galantamine or benzgalantamine in patients with severe hepatic impairment (Child-Pugh score of 10 to 15) is not recommended.

Galantamine has a moderate potential interaction with Peptic Ulcer.

The use of cholinesterase inhibitors is associated with an increase in gastric acid secretion and gastric contractions. Monitor for symptoms of active or occult gastrointestinal bleeding, especially in patients at increased risk for developing ulcers (e.g., history of ulcer disease or concurrent use of nonsteroidal anti-inflammatory drugs).

The atomoxetine in Atoncy has a major potential interaction with Pheochromocytoma.

Atomoxetine is contraindicated in patients with pheochromocytoma or a history of pheochromocytoma. Serious reactions, including elevated blood pressure and tachyarrhythmia, have been reported in patients with pheochromocytoma or a history of pheochromocytoma who received atomoxetine.

The atomoxetine in Atoncy has a major potential interaction with Psychosis.

Atomoxetine increased the risk of suicidal ideation in pediatric patients with ADHD, and patients should be monitored closely for suicidal thoughts and behavior, clinical worsening, or unusual behavioral changes, especially during initial therapy or dosage changes. Before initiating atomoxetine, patients should be screened for bipolar disorder risk factors, and discontinuation should be considered if treatment-emergent psychotic or manic symptoms occur.

Galantamine has a moderate potential interaction with Renal Dysfunction.

In patients with creatinine clearance of 9 to 59 mL/min, the dosage of galantamine or benzgalantamine should generally not exceed 16 mg/day or 20 mg/day, respectively. In patients with creatinine clearance less than 9 mL/min, the use of galantamine or benzgalantamine is not recommended.

Galantamine has a moderate potential interaction with Seizures.

Cholinesterase inhibitors have been associated with convulsions and tremor. Therapy with cholinesterase inhibitors should be administered cautiously in patients with seizure disorders. Patients with Alzheimer's disease should be closely monitored for seizures.